iPS Cells & Regenerative Medicine– category –
-
FUJIFILM Cellular Dynamics Quadruples iPSC Manufacturing Capacity with $200M New Facility in Wisconsin, Meeting Soaring Cell Therapy Demand
Manufacturing Dive USA Overview FUJIFILM Cellular Dynamics (FCDI) has inaugurated a new headquarters and iPSC development and manufacturing facility in Madison, Wisconsin, backed by a $200 million investment. This 170,000 square-foot exp... -
CRISPR Gene Editing Evolves with Cas12a2 to Shred Sick Cell DNA, Expanding Therapeutic Horizons for Cancer and Viral Infections
Top Doctor Magazine USA Overview The CRISPR gene editing landscape is rapidly evolving in 2026, driven by the FDA approval of Cas9-based CASGEVY and the discovery of the novel Cas12a2 protein's ability to 'shred' diseased cell DNA. Unlik... -
iPS Cells & Regenerative Medicine Weekly Report May 24, 2026
🎙 Podcast May 24, 2026 (MP3) — Play & Download iPS_RegenerativeMedicineEnglishPodcast_20260524.mp3Download -
Vertex Pharmaceuticals Secures CASGEVY Reimbursement Agreement in Germany for Sickle Cell Disease and Beta Thalassemia
Vertex Pharmaceuticals USA Overview Vertex Pharmaceuticals announced a reimbursement agreement in Germany for CASGEVY (exa-cel), a groundbreaking gene-editing therapy for sickle cell disease (SCD) and transfusion-dependent beta thalassem... -
iPSC-Derived Retinal Sheet Transplantation for Retinitis Pigmentosa: Clinical Trial Validates Long-Term Safety and Engraftment
臨床研究等提出・公開システム (jRCT) Japan Overview A pioneering clinical study (jRCTa050200027) conducted by Kobe City Eye Center Hospital has concluded, affirming the long-term safety and engraftment of allogeneic iPSC-derived retinal s... -
SelectBIO to Host Lipid Nanoparticles (LNPs) Asia/Pacific 2026: Driving mRNA Delivery Innovations
SelectBIO Conferences UK Overview SelectBIO Conferences will host the 'Lipid Nanoparticles (LNPs) Asia/Pacific 2026' event, focusing on LNPs, extracellular vesicles, exosomes, and Japanese research. The conference will primarily address ... -
The Future of Healing: Gene Therapy in 2026 Navigates CRISPR Advances and Access Challenges
薬事日報 Japan Overview By 2026, gene therapy is undergoing a paradigm shift, moving towards direct repair or replacement of disease-causing genes. CRISPR-based in vivo editing shows early clinical promise, pushing the vision of single-i... -
iPSC-Derived Cell Therapy Pipeline 2026: From Disease Modeling to Expanding Clinical Applications
BioInformant USA Overview As of 2026, the iPSC-derived cell therapy pipeline shows rapid advancements in disease modeling and drug discovery, though broad clinical use in human patients still faces challenges. iPSC-derived cells hold imm... -
iRegene Therapeutics’ NouvNeu001 Secures Dual FDA Expedited Designations: A New Regulatory Milestone for iPSC Therapies
RegMedNet UK Overview iRegene Therapeutics announced its allogeneic iPSC-derived therapy, NouvNeu001, received Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. FDA for Parkinson's disease, following its prior Fast ... -
CRISPR Therapeutics Honored with 2026 Global Recognition Award for Pioneering Gene-Editing Advances
Global Recognition Awards USA Overview CRISPR Therapeutics received the 2026 Global Recognition Award for its significant advancements in gene editing and personalized medicine. Leveraging CRISPR-Cas9 technology, the company has develope...
